Academic literature on the topic 'Therapeutic use'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Therapeutic use.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Therapeutic use"

1

Neekhra, Sachin, Himani Awasthi, and DCP Singh. "Potential Therapeutic use of Streblus asper: A Review." International Journal of Research and Development in Pharmacy & Life Sciences 6, no. 7 (December 2017): 2845–49. http://dx.doi.org/10.21276/ijrdpl.2278-0238.2017.6(7).2845-2849.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Dvorak, J. "Therapeutic use exemption." British Journal of Sports Medicine 40, Supplement 1 (July 1, 2006): i40—i42. http://dx.doi.org/10.1136/bjsm.2006.027490.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Nadler, S. F., M. A. Prybicien, D. Sicher, G. A. Malanga, M. DePrince, and J. E. Bowen. "THERAPEUTIC MODALITY USE." Medicine & Science in Sports & Exercise 33, no. 5 (May 2001): S90. http://dx.doi.org/10.1097/00005768-200105001-00519.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Pradhan, Leena, Nicholas D. Andersen, Christoph Nabzdyk, Frank W. LoGerfo, and Aristidis Veves. "Wound-healing Abnormalities in Diabetes and New Therapeutic Interventions." US Endocrinology 00, no. 01 (2007): 68. http://dx.doi.org/10.17925/use.2007.00.1.68.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Gallagher, Lisa M., and Francois Bethoux. "Therapeutic use of the Arts for Patients with Multiple Sclerosis." US Endocrinology 13, no. 02 (2017): 82. http://dx.doi.org/10.17925/use.2017.13.02.82.

Full text
Abstract:
People with multiple sclerosis (MS) face a wide variety of physical, emotional, and social challenges. A multidisciplinary comprehensive care approach is recommended for the management of MS and its consequences, and non-traditional treatments are increasingly considered by patients and health care providers, particularly for the promotion of wellness in the context of this chronic disease. Previous research has demonstrated the benefits of the therapeutic arts (art therapy, dance and movement therapy, and music therapy) in addressing some of the physiological, psychological, cognitive, social, and spiritual needs of patients facing a variety of chronic illnesses. Our review of the literature suggests that therapeutic art can be beneficial to individuals with MS, particularly in promoting self-efficacy, emotional well-being, and motor control. However, the body of evidence is limited, and further research is needed regarding the outcomes and mechanism of action of therapeutic arts in MS to better understand their role in the management of the consequences of the disease.
APA, Harvard, Vancouver, ISO, and other styles
6

Groeneweg, Stefan, Robin P. Peeters, Theo J. Visser, and W. Edward Visser. "Diagnostic and Therapeutic Challenges in the Allan—Herndon—Dudley Syndrome." US Endocrinology 12, no. 02 (2016): 90. http://dx.doi.org/10.17925/use.2016.12.02.90.

Full text
Abstract:
Thyroid hormone (TH) is important for normal brain development. The TH transporter protein monocarboxylate transporter 8 (MCT8) is crucial to maintain adequate TH levels in the brain during development and throughout life. Mutations in MCT8 result in the Allan–Herndon–Dudley syndrome (AHDS), which is characterized by a severe delay in neurocognitive development, combined with abnormal serum thyroid function tests (TFTs). The combination of an increased (F)T3 and decreased (F)T4 and rT3 serum levels are characteristic for the presence of AHDS in male patients with moderate to severe delay in neurocognitive development. Here, we provide an overview of current insights, challenges and pitfalls in the diagnosis and management of patients with AHDS.
APA, Harvard, Vancouver, ISO, and other styles
7

Tan, Robert S., Chris Ojeih, and Maurita Carrejo. "Potential Therapeutic Role of Androgens in Cognitive Loss Associated with Hypogonadism." US Endocrinology 00, no. 01 (2005): 1. http://dx.doi.org/10.17925/use.2005.00.01.1a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Tan, Robert S., Chris Ojeih, and Maurita Carrejo. "Potential Therapeutic Role of Androgens in Cognitive Loss Associated with Hypogonadism." US Endocrinology 00, no. 01 (2005): 84. http://dx.doi.org/10.17925/use.2005.00.01.84.

Full text
Abstract:
Memory problems late in life are common and are often easy to recognize. Hypogonadism in older men is not as readily identified, but it is also frequently a part of aging. Androgens, such as testosterone, have important hormonal influences on the brain and may prevent and possibly treat cognitive loss, including age-associated memory loss, mild cognitive impairment (MCI), and perhaps even Alzheimer’s disease (AD).There is support from small, prospective clinical trials that suggest the role of testosterone in improving cognitive function in normal men as well as hypogonadal men with AD. This improvement in cognitive function is subtle and is often only measurable on specialized neuropsychological batteries such as those that measure the visual-spatial domain. Patients often report measurable memory improvement in both declarative and procedural domains after receiving testosterone replacement therapy.The rise of gonadotropins, follicle-stimulating hormones (FSHs), and luteinizing hormones (LHs), has been associated with AD.The clinical significance of therapeutic strategies directed to reduce these levels remains to be determined. Current evidence showing that dehydroepiandrosterone (DHEA) improves cognitive function is ambiguous.
APA, Harvard, Vancouver, ISO, and other styles
9

Rodriguez, Mariano, Juan Munoz-Castaneda, and Yolanda Almaden. "Therapeutic Use of Calcitriol." Current Vascular Pharmacology 12, no. 2 (April 2014): 294–99. http://dx.doi.org/10.2174/15701611113119990021.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Wall, Jenny, Sally Davis, and Samantha Ridgway. "Cannabis: its therapeutic use." Nursing Standard 16, no. 10 (November 21, 2001): 39–44. http://dx.doi.org/10.7748/ns2001.11.16.10.39.c3123.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Dissertations / Theses on the topic "Therapeutic use"

1

Xiang, Hong. "Effects of myo-inositol and, or triiodothyronine (T₃) treatment on cardiac dysfunction and elevated myocardial lipid levels in STZ-diabetic rats." Thesis, University of British Columbia, 1987. http://hdl.handle.net/2429/26675.

Full text
Abstract:
A number of experimental studies have implied a link between diabetes-induced lipid accumulation in the myocardium and the development of cardiomyopathy. Since diabetics excrete large amounts of myo-inositol which is a lipotropic agent, this study was undertaken to investigate the effects of myo-inositol on the elevated myocardial lipid levels and the depressed cardiac performance of diabetic rats. Diabetes was induced in female Wistar rats (190-215 g) with streptozotocin (STZ) (55 mg/kg, i.v.). Three days after diabetes induction, myo-inositol was administered in the drinking water (2.5 g/kg/day) for a 8 week period. Untreated diabetics exhibited a loss of body weight, hyperglycemia, hypoinsulinemia and hypothyroidism. These effects were not altered after myo-inositol treatment. STZ-diabetes also produced a significant elevation of plasma and myocardial triacylglycerol, cholesterol and phospholipid. Myo-inositol treatment decreased these lipid levels. In addition, hearts from diabetic animals had a decreased ability to develop left ventricular developed pressure (LVDP) and both the rate of pressure rise (+dP/dt) and the rate of pressure decline (-dP/dt) were also reduced. Hearts from myo-inositol-treated diabetic animals showed a partial but definite improvement of cardiac function. As diabetes-induced hypothyroidism was not altered after myo-inositol supplementation, a combination treatment of both myo-inositol (2.5 g/kg/day, p.o. daily) and T₃ (30 ug/kg/day, s.c. daily) was then undertaken to determine whether heart function of diabetic rats could be further improved. STZ-diabetic rats were characterized by a loss of body weight, hyperglycemia and hypoinsulinemia; none of which were altered by either T₃ or myo-inositol plusT₃ treatment. T₃ treatment normalized the thyroid state of diabetic animals as shown by Tahiliani and McNeill (1984). However, plasma and myocardial triacylglycerol, cholesterol and phospholipid levels of diabetic rats either remained elevated or were further increased with T₃ or myo-inositol plus T₃ treatment. In addition, T₃ treatment alone did not prevent cardiac dysfunction in diabetic rats. There was, however, some improvement in heart function in the groups treated with both myo-inositol and T₃, but the improvement was not as pronounced as with myo-inositol treatment alone.
Pharmaceutical Sciences, Faculty of
Graduate
APA, Harvard, Vancouver, ISO, and other styles
2

Ramez-Baydoun, Lubna Lulu. "Novel chelating agents for therapeutic use." Thesis, King's College London (University of London), 2004. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.406043.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Marnewick, Jeanine Lucasta. "Cancer modulating properties of unique South African herbal teas (rooibos and honeybush) in short term in vitro and in vivo carcinogenesis assays." Thesis, Stellenbosch : Stellenbosch University, 2004. http://hdl.handle.net/10019.1/21888.

Full text
Abstract:
Dissertation (PhD)--University of Stellenbosch, 2004.
ENGLISH ABSTRACT: This thesis provides the first scientific evidence on the cancer modulating properties of two unique South African herbal teas, rooibos (Aspalathus Iinearis) and honeybush (Cyclopia intermedia) utilizing in vitro as well as in vivo carcinogenesis assays by: • Demonstrating the in vitro antimutagenic activity of aqueous extracts of the herbal teas against the metabolic activated mutagens, 2-acetylaminofluorene (2- AAF) and the mycotoxin, aflatoxin B1 (AFB,) as well as, to a certain extent, against the direct acting mutagen, hydrogen peroxide, utilizing the Salmonella typhimurium mutagenicity assay. • Increasing the activity of hepatic drug metabolizing enzymes, glutathione Stransferase alpha and UPD-glucuronosyl transferase, and reduced the oxidative stress by stabilizing the level of reduced glutathione (GSH) resulting in an increased hepatic reduced to oxidized glutathione ratio (GSG:GSSG). No toxic effects were noticed in rats consuming the herbal teas for 10 weeks as their sole source of drinking fluid. • Demonstrating the ex vivo modulation of 2-AAF- and AFB1-induced mutagenesis by sub- cellular hepatic fractions of rats consuming the herbal teas in the Salmonella mutagenicity assay. Hepatic cytosolic fractions protected against mutagenesis of both mutagens, while the microsomal fractions exhibited a reduced capacity to metabolize AFB1 to its active mutagenic metabolite. • Providing evidence for the in vivo modulation of tumour promotion using the liver as well as the two-stage skin carcinogenesis animal models. The unprocessed herbal teas arrested proliferation of the placental form of glutathione-Stransferase (GSTP+) altered cells as well as reduced the total number of enzyme altered foci in the liver of rats. Topical application of polyphenolic fractions of the various herbal teas prior to 12-0-tetra-decanoylphorbol-13-acetate (TPA) tumour promotion, reduced tumour formation in mouse skin initiated with 7,12-dimethylbenz[ ajanthracene (DMBA). The protective effect was illustrated by a decreased tumour incidence, a reduction in tumour volume as well as a delayed onset of tumour development. The f1avanol/proanthocyanidin content of the fractions could playa major role in the protection against skin tumour promotion. • Proposing possible mechanisms whereby rooibos and honeybush herbal teas could exert their cancer modulating properties with respect to in vitro and ex vivo antimutagenicity, in vivo oxidative status and reduced tumour promotion. • Providing evidence that the herbal teas mimic the cancer modulating properties of green and black teas although differences exist, presumably due to differences in the polyphenolic constituents. • Suggesting that rooibos and honeybush herbal teas may play an important role as chemopreventive agents in the modulation of cancer.
AFRIKAANSE OPSOMMING: Hierdie tesis bevat die eerste ondersoek na die effek van waterige en polifenoliese ekstrakte van rooibos (Aspalathus Iinearis) en heuningbos (Cyclopia intermedia) op verskeie aspekte van kankerontwikkeling. Die twee kruietees is uniek aan Suid-Afrika en kan 'n belangrike rol speel in die voorkoming van kanker. Verskillende in vitro so wei as in vivo studies het die volgende getoon: • Antimutageniese aktiwiteite teen die metabolies-geaktiveerde mutagene, 2- asetielaminofluoreen (2-AAF) en die mikotoksien, aflatoksien B1 (AFB1) in die Salmonella fyphimurium mutagenisiteitstoets. 'n Beperkte mate van beskerming is ook verleen teen die oksidatiewe mutageen, waterstofperoksied, sonder metaboliese aktivering. • Verhoogde aktiwiteite van die fase II ensieme, glutatioon S-tranferase alfa en UDP-glukuronidase, wat liggaamsvreemde verbindings metaboliseer. Die kruietees verlaag die oksidasietoestand soos weerspieel word deur 'n toename van gereduseerde glutatioon tot die geoksideerde vorm in die lewer van rotte wat 10 weke hierdie kruietees gedrink he!. Die kruietees het geen toksiese uitwerking op die rotte gehad nie. • Antimutageniese aktiwiteite van subselluiE~re fraksies van die lewer teenoor 2- AAF en AFB1 in die Salmonella toets. Die sitosolfraksie van die rotlewer bied beskerming teen die ge"induseerde mutagenese van beide mutagene, terwyl die mikrosomale fraksie ook die metaboliese aktivering van AFB1 na die aktiewe mutageniese metaboliet verminder. • In vivo modulering van kankerpromosie met behulp van bekende rotlewer en muisvel kankerontwikkelingsmodelle. In die lewermodel het die ongeprosesseerde kruietees beide die ontwikkeling en getal van GSTP+ fokusse onderskeidelik vertraag en verminder. In die geval van die velkankermodel het aanwending van polifenoliese fraksies van die kruietees beskerming gebied teen die ontwikkeling van velkankers by muise. Die aantal en grootte van die tumors het afgeneem terwyl die verskyning daarvan ook vertraag is. • Verskeie meganismes waardeur rooibos- en heuningboslee moonllik kanker kan moduleer word voorgeslel. Verskille in die polifenoliese sameslelling asook hul onderskeie konsenlrasies kan 'n belangrike rol speel in die kankerveranderende effekle van die lees. • Oal gereelde inname van rooibos- en/of heuningboslee moonllik 'n belangrike rol kan speel in die voorkoming van dieel- en omgewings-geYnduseerde kankers.
APA, Harvard, Vancouver, ISO, and other styles
4

Cheng, Ka-wing, and 鄭家榮. "Preventive potential and mechanism of dietary phenolics on the formation of mutagenic heterocyclic amines." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2009. http://hub.hku.hk/bib/B4284177X.

Full text
Abstract:
The Best PhD Thesis in the Faculties of Dentistry, Engineering, Medicine and Science (University of Hong Kong), Li Ka Shing Prize,2008-2009
published_or_final_version
Biological Sciences
Doctoral
Doctor of Philosophy
APA, Harvard, Vancouver, ISO, and other styles
5

Stapleton, Graham Neil. "A study of the effects of sucralfate in the bile duct litigated pig peptic ulcer model with particular reference to the effects on the physico-chemical properties of gastric mucus and including comparisons with famotidine and misoprostol." Master's thesis, University of Cape Town, 1992. http://hdl.handle.net/11427/25727.

Full text
Abstract:
Sucralfate is a drug that effectively heals duodenal, gastric and oesophageal ulcers. It is not absorbed systemically and it has been shown to act locally by coating the ulcer base. However when it was also shown to prevent stress ulcers and ethanolinduced gastric mucosa! lesions, it seemed likely that it acted in some way to improve the effectiveness of the gastric mucosa! barrier. Some investigators suggested that it did so by stimulating local prostaglandin release. The Slomiany group, on the basis of in vitro work on the effects of Sucralfate on pig gastric mucus, claimed that Sucralfate acted by altering the physico-chemical properties of mucus to increase the viscosity and retard the back diffusion of H+ ions. The work described in this dissertation set out to verify, in vivo, these claimed effects on mucus, using an experimental porcine model of peptic ulceration, the bile duct ligated pig. In addition, the effects of Sucralfate were compared with those of Famotidine and Misoprostol, and changes in mucous prostaglandins, gastric juice pepsin and gastric flora were sought. By way of introduction, the known and postulated actions of Sucralfate, current understanding of gastric mucus physiology and pathogenesis of peptic ulceration, have been reviewed, as have experimental animal models of peptic ulceration, in order to justify using the bile duct ligated pig model.
APA, Harvard, Vancouver, ISO, and other styles
6

Betz, Jennifer. "The Use of Improvisation in Therapeutic Practices." Kent State University Honors College / OhioLINK, 2019. http://rave.ohiolink.edu/etdc/view?acc_num=ksuhonors1557312650223249.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Parsons, Ann Bernardene. "Designing a resource guide for horticultural therapy programs at botanical gardens and arboreta." Thesis, Virginia Polytechnic Institute and State University, 1985. http://hdl.handle.net/10919/104531.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

余詩德 and Sze-tak Yu. "Effects of Chinese green tea and tea catechins on lipolysis." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 1999. http://hub.hku.hk/bib/B31969677.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Zhang, Jingjing, and 张晶晶. "The anti-cancer properties of cyclometalated gold(III) complexes and organogold(III) supramolecular polymers." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2014. http://hdl.handle.net/10722/208171.

Full text
Abstract:
Prompted by the successful clinical application of cisplatin in cancer therapy, worldwide efforts have been devoted to develop new metal-based drugs for anticancer treatment. Gold(III) complexes at first received attention as anti-cancer drug candidates because of their square-planar geometry which resembles that of platinum(II) complexes. Subsequent studies revealed that various gold(III) complexes displayed promising anti-cancer activities with different biological mechanisms. Although some achievements have been obtained in the development of anti-cancer gold(III) complexes, challenges including the improvement of bioavailability, stability and selectivity, elucidation of the action mechanisms, and the development of novel delivery approaches of gold(III) complexes to reduce systematic toxicity, remain to be exploited. A panel of anti-cancer complexes [AuIII(R-C^N)(L)]n+ (wherein HC^N is 2-phenylpyridine, L is biguanide or biuret) have been identified and described in Chapter 3. Biguanide or biuret have been employed to improve the solubility of the complexes in aqueous solutions. Meanwhile, the lipophilicity could readily be adjusted by varying the R group to obtain a balance between lipophilicity and aqueous solubility. Among the synthesized complexes, the cationic complexes, [AuIII(butyl-C^N)biguanide]Cl (3.1) and [AuIII(C^N)biguanide]Cl (3.2) are soluble in aqueous solutions with solubility over 5 mg/mL. Besides, introduction of butyl groups to 3.1 and [AuIII(butyl-C^N)biuret] (3.3) resulted in higher cellular uptake of gold, which might enhance their cytotoxic activities (IC50 values: 1.5–17 μM) compared with 3.2 and [AuIII(C^N)biuret] (3.4) (IC50 values: 9.4–47.3 μM). Moreover, 3.1 was also found to induce cell cycle arrest in S-phase and endoplasmic reticulum (ER) damage in human cervical epithelial carcinoma (HeLa) cells, and display significant anti-angiogenic activity at its sub-cytotoxic concentrations. In Chapter 4, a series of gold(III) complexes with dithiocarbamate and 2-phenylpyridine ligands to target deubiquitinases (DUBs), have been designed. These complexes achieved significant inhibition on purified DUBs. Notably, [AuIII(2-(4-nbutylphenyl) pyridyl)(diethyldithiocarbamate)]PF6 (4.1) inhibited both the purified (IC50 values: 46–223 nM) and cell-based DUBs activities with high efficiency. Its interaction with DUB UCHL1 and peptides which are present in several types of DUBs and contain active cysteine residue were confirmed by mass spectrometric analysis. All complexes displayed significant cytotoxicities, and those containing diethyldithiocarbamate ligand displayed specific cytotoxicity on breast cancer cells. Accumulation of a tumor suppressor p53, cell-cycle arrest, and apoptotic cell death were induced in breast cancer cells by 4.1. Besides, 4.1 also showed anti-angiogenic effects. These biological activities might be related with DUBs inhibition. In Chapter 5, a cytotoxic complex [AuIII(C^N^C)(4-dpt)](CF3SO3) (5.1, HC^N^CH = 2,6-diphenylpyridine; 4-dpt = 2,4-diamino-6-(4-pyridyl)-1,3,5-triazine) has been designed to self-assemble into supramolecular polymers (5.1-SP) in acetonitrile. In physiologically relevant solutions, 5.1-SP displayed a sustained-release property of the anti-angiogenic ligand 4-dpt, and in the presence of glutathione (GSH), [AuIII(C^N^C)-GSH] adduct(s) were also gradually released. The supramolecular polymers 5.1-SP also showed selective cytotoxicity toward cancerous cells, and could act as drug-carriers of other cytotoxic agents to achieve sustained-release behavior.
published_or_final_version
Chemistry
Doctoral
Doctor of Philosophy
APA, Harvard, Vancouver, ISO, and other styles
10

Roberts, Jacintha. "Studies on bisphosphonate elution from orthopaedic implants." Thesis, McGill University, 2008. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=112582.

Full text
Abstract:
In a 6-week rat model it was demonstrated that a small dose of peri-implant zoledronic acid (ZA) increased local bone formation 3-fold compared with controls. Ancillary in vitro studies using 14C-labeled ZA implant doses demonstrated biphasic elution profiles for implants coated with hydroxyapatite; complete ZA release occurred within one to three weeks in serum compared with only 60% ZA release after 12 weeks in water. Implants without hydroxyapatite coating showed more burst-type release profiles and full ZA elution within 24 hours of hydration in serum or water. Canine studies at 6 weeks using implants with 14C-labeled ZA showed that the compound remained localized, with the greatest ZA concentration immediately adjacent to the implant. Although there was evidence of skeletal ZA distribution via diffusion into the circulation, the levels were two orders of magnitude less than at the implant site.
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Therapeutic use"

1

Jens, Kurreck, ed. Therapeutic oligonucleotides. Cambridge, UK: RSC Pub., 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Raphael, Mechoulam, ed. Cannabinoids as therapeutic agents. Boca Raton, Fla: CRC Press, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Tekinay, Ayse B., and Mustafa Ö. Güler. Therapeutic nanomaterials. Hoboken, New Jersey: John Wiley & Sons, Inc., 2016.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Labate, Beatriz Caiuby, and Clancy Cavnar, eds. The Therapeutic Use of Ayahuasca. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-642-40426-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Wosket, Val. The Therapeutic Use of Self. Classic edition. | Milton Park, Abingdon, Oxon ;: Routledge, 2016. http://dx.doi.org/10.4324/9780203772263.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Mackway-Girardi, AnnMarie. Therapeutic use of interleukin-2. Bethesda, MD: U.S. DHHS, PHS, National Institutes of Health, National Cancer Institute, International Cancer Research Data Bank, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

M, Sondel Paul, and International Cancer Research Data Bank., eds. Therapeutic use of interleukin-2. Bethesda, MD: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, International Cancer Research Data Bank, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Nath, Dwivedi Kedar, ed. The therapeutic use of stories. London: Routledge, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Yuti, Chernajovsky, and Nissim Ahuva, eds. Therapeutic antibodies. Berlin: Springer, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Béla, Scheiber, and Selby Carla, eds. Therapeutic touch. Amherst, N.Y: Prometheus Books, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Therapeutic use"

1

Read, Daniel, James Skinner, Daniel Lock, and Aaron CT Smith. "Therapeutic use exemptions." In WADA, the World Anti-Doping Agency, 102–23. First. | Milton Park, Abingdon, Oxon ; New York NY : Routledge, 2021. | Series: Routledge research in sport and corruption: Routledge, 2021. http://dx.doi.org/10.4324/9781003084297-6-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Selekman, Matthew D. "Therapeutic Brick Walls." In The Therapist’s Use of Self, 110–40. New York: Routledge, 2023. http://dx.doi.org/10.4324/9781003334460-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Wiltenburg, Victor Distefano, Dianne da Rocha Prado, and Fúlvio Rieli Mendes. "Therapeutic Use of Hallucinogens." In Drugs and Human Behavior, 479–510. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-62855-0_35.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lanzotti, Virginia. "Diterpenes for Therapeutic Use." In Natural Products, 3173–91. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-642-22144-6_192.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Froehlich, Jan. "Therapeutic Use of Self." In Occupational Therapy Essentials for Clinical Competence, 133–47. 3rd ed. New York: Routledge, 2024. http://dx.doi.org/10.4324/9781003525295-12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Polatajko, Helene J., Jane A. Davis, and Sara E. McEwen. "Therapeutic Use of Self." In Occupational Therapy, 81–92. 4th ed. Boca Raton: Routledge, 2024. http://dx.doi.org/10.4324/9781003522997-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Aranki, S. F., F. Mannting, S. K. Shernan, N. C. Cummings, S. P. Sears, and L. H. Cohn. "Transmyocardial Laser Use for Endstage Coronary Artery Disease." In Therapeutic Angiogenesis, 163–73. Berlin, Heidelberg: Springer Berlin Heidelberg, 1999. http://dx.doi.org/10.1007/978-3-662-03776-8_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Chugh, Atul R., Samir N. Patel, Venkataraman Rajaram, Rachel Neems, Matt Feinstein, Marshall Goldin, and Steven B. Feinstein. "The Clinical Use of Noninvasive Modalities in the Assessment of Atherosclerosis." In Therapeutic Lipidology, 389–408. Totowa, NJ: Humana Press, 2007. http://dx.doi.org/10.1007/978-1-59745-533-6_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Torres-Gómez, Mariano. "Human Medicinal Mushroom Use." In Therapeutic Mushrooms for Diabetes Mellitus, 35–66. New York: Apple Academic Press, 2023. http://dx.doi.org/10.1201/9781003332046-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Bartolomei, Mirco, and Giovanni Paganelli. "Intracavitary Use of Radionuclides and Treatment of Meningiomas." In Therapeutic Nuclear Medicine, 207–14. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/174_2012_693.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Therapeutic use"

1

Fikar, Peter, Florian Güldenpfennig, and Roman Ganhör. "The Use(fulness) of Therapeutic Toys." In DIS '18: Designing Interactive Systems Conference 2018. New York, NY, USA: ACM, 2018. http://dx.doi.org/10.1145/3196709.3196721.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Dahl, Elizabeth. "Towards the use of HIFU, in Conjunction with Surgery, in the Treatment of Malignant Brain Tumors." In THERAPEUTIC ULTRASOUND: 5th International Symposium on Therapeutic Ultrasound. AIP, 2006. http://dx.doi.org/10.1063/1.2205469.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

McLaughlan, James. "The Design And Implementation Of A Passive Cavitation Detection System For Use With Ex Vivo Tissue." In THERAPEUTIC ULTRASOUND: 5th International Symposium on Therapeutic Ultrasound. AIP, 2006. http://dx.doi.org/10.1063/1.2205493.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Baldaque-Silva, F., J. P. Pereira, V. Miroslav, W. Naining, and M. Omae. "Are single use endoscopes suitable for therapeutic endoscopy?" In ESGE Days 2024. Georg Thieme Verlag KG, 2024. http://dx.doi.org/10.1055/s-0044-1783510.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Bera, Jean-Christophe, Bruno Gilles, Izella Saletes, Claude Inserra, and Hiva Shamsborhan. "Numerical study of cavitation threshold by use of bifrequency excitation." In 11TH INTERNATIONAL SYMPOSIUM ON THERAPEUTIC ULTRASOUND. AIP, 2012. http://dx.doi.org/10.1063/1.4757304.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Payne, A., A. Blankespoor, N. Todd, U. Vyas, D. Christensen, D. Parker, R. Roemer, and Emad S. Ebbini. "Optimization of HIFU Treatments for Use in Model Predictive Control." In 8TH INTERNATIONAL SYMPOSIUM ON THERAPEUTIC ULTRASOUND. AIP, 2009. http://dx.doi.org/10.1063/1.3131406.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kaneko, Yukio. "The Design Of Microbubbles Specialized For Therapeutic Or Diagnostic Use." In 4TH INTERNATIONAL SYMPOSIUM ON THERAPEUTIC ULTRASOUND. AIP, 2005. http://dx.doi.org/10.1063/1.1901643.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Wong, Serena H., Ronald D. Watkins, Mario Kupnik, Kim Butts Pauly, B. T. Khuri-Yakub, and Emad S. Ebbini. "Progress in Development of HIFU CMUTs for use under MR-guidance." In 8TH INTERNATIONAL SYMPOSIUM ON THERAPEUTIC ULTRASOUND. AIP, 2009. http://dx.doi.org/10.1063/1.3131441.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Payne, Allison H., Dennis L. Parker, Jeff Moellmer, Robert B. Roemer, and Sarah Clifford. "Characterization of an Isolated Kidney’s Vasculature for Use in Bio-Thermal Modeling." In 6TH INTERNATIONAL SYMPOSIUM ON THERAPEUTIC ULTRASOUND. AIP, 2007. http://dx.doi.org/10.1063/1.2744297.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Amato, Federica, Marianna Di Gregorio, Clara Monaco, Monica Sebillo, Genoveffa Tortora, and Giuliana Vitiello. "The Therapeutic Use of Humanoid Robots for Behavioral Disorders." In AVI '20: International Conference on Advanced Visual Interfaces. New York, NY, USA: ACM, 2020. http://dx.doi.org/10.1145/3399715.3399960.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Therapeutic use"

1

Evans, Holly. The Use of Filariae as a Therapeutic Agent for Hypersensitivity Diseases. Fort Belvoir, VA: Defense Technical Information Center, November 2014. http://dx.doi.org/10.21236/ad1012825.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Lillo, Antonietta. Harnessing in vitro evolution to discover antibodies for therapeutic and diagnostic use. Office of Scientific and Technical Information (OSTI), March 2021. http://dx.doi.org/10.2172/1773320.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Baldi, Emilio. The Use of Extremely Low Frequencies (ELF) in Pulsed Form (PELF) for Therapeutic Use: A Pilot Study. Fort Belvoir, VA: Defense Technical Information Center, October 2001. http://dx.doi.org/10.21236/ada409410.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Templeton, Charles B., Mark A. Poli, and Rikki Solow. Prophylactic and Therapeutic Use of an Anti-Brevetoxin (PbTx-2) Antibody in Conscious Rats. Fort Belvoir, VA: Defense Technical Information Center, May 1988. http://dx.doi.org/10.21236/ada210932.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

O'Keefe, Denise S., and Warren D. Heston. Characterization of Prostate-Specific Membrane Antigen (PSMA) for Use in Therapeutic and Diagnostic Strategies Against Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, June 2002. http://dx.doi.org/10.21236/ada407353.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Klimas, Nancy G., and Mary A. Fletcher. The Use of Comprehensive Molecular Profiling With Network and Control Theory to Better Understand GWI and Model Therapeutic Strategies. Fort Belvoir, VA: Defense Technical Information Center, July 2010. http://dx.doi.org/10.21236/ada529400.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Klimas, Nancy G., and Mary A. Fletcher. The Use of Comprehensive Molecular Profiling with Network and Control Theory to Better Understand GWI and Model Therapeutic Strategies. Fort Belvoir, VA: Defense Technical Information Center, July 2012. http://dx.doi.org/10.21236/ada568442.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Klimas, Nancy G., and Mary A. Fletcher. The Use of Comprehensive Molecular Profiling with Network and Control Theory to Better Understand GWI and Model Therapeutic Strategies. Fort Belvoir, VA: Defense Technical Information Center, July 2011. http://dx.doi.org/10.21236/ada554188.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Sentcоv, Valentin, Andrei Reutov, and Vyacheslav Kuzmin. Electronic training manual "Acute drug poisoning". SIB-Expertise, January 2024. http://dx.doi.org/10.12731/er0776.29012024.

Full text
Abstract:
The widespread use in modern medicine of hypnotics, sedatives, tricyclic antidepressants, antihypertensive drugs and antipyretics, even in therapeutic dosages, sometimes leads to adverse consequences for the patient. Accidental or intentional excess of therapeutic dosages leads to severe poisoning. This fact indicates the high relevance of doctors’ knowledge of any clinical specialty and the treatment of poisoning by these groups of drugs. This electronic educational resourse consists of six theoretical educational modules: poisoning with barbituric acid derivatives, acute poisoning with tricyclic antidepressants, acute poisoning with beta-blockers, poisoning with clonidine, acute poisoning with anti-tuberculosis drugs, acute poisoning with paracetamol. The theoretical block of modules is presented by presentations, the text of lectures with illustrations. Control classes in the form of test control accompany each theoretical module. After studying all modules, the student passes the final test control. Mastering the electronic educational resourse will ensure a high level of readiness to provide specialized toxicological care by doctors of various specialties.
APA, Harvard, Vancouver, ISO, and other styles
10

Albuquerque, Nila, Franklin Regis, and Lucas Machado. Analysis of effectiveness, costs, quality of life, adherence and safety of the use of adalimumab in adults diagnosed with moderate to severe hidradenitis suppurativa: systematic review protocol. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, October 2021. http://dx.doi.org/10.37766/inplasy2021.10.0010.

Full text
Abstract:
Review question / Objective: What evidence is available in longitudinal studies on the use of adalimumab for the treatment of moderate to severe hidradenitis suppurativa in adults with a diagnosis of moderate to severe hidradenitis suppurativa in which systemic antibiotic therapy has been shown to be ineffective and/or in situations where they present intolerance or contraindication to systemic antibiotics, compared to the application of usual care without the use of adalimumab, regarding the reduction in the total count of abscesses and nodules, decreased sensation of pain, therapeutic adherence, increased levels of self-esteem and quality of life, improvement in inflammatory nodules, abscesses and fistulas costs and expenses associated with the treatment of the disease? Condition being studied: Moderate to severe hidradenitis suppurativa.
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography